FDA blocks publication of Covid-19 and shingles vaccine safety studies
Updated
Updated · The New York Times · May 5
FDA blocks publication of Covid-19 and shingles vaccine safety studies
9 articles · Updated · The New York Times · May 5
HHS spokesman Andrew Nixon said officials withdrew two Covid studies in October and withheld conference abstracts on Shingrix research in February after analyses of millions of patient records.
Agency scientists had found serious side effects were very rare, and the studies had cost millions of dollars in public funds.
The move adds to broader administration actions limiting vaccine information, including cuts to development funding and blocking other research supporting Covid vaccine safety and effectiveness.
Why were studies supporting vaccine safety blocked despite using millions of patient records and public funding, and what does this mean for scientific transparency?
How might recent funding cuts and new drug approval policies at the FDA affect future vaccine development and disease prevention efforts?
What are the potential consequences for public health if positive vaccine safety studies are withheld or blocked by regulatory agencies?